Literature DB >> 18765092

Beyond brachial pressure effect.

Eduardo Pimenta, Suzanne Oparil.   

Abstract

Year:  2008        PMID： 18765092     DOI： 10.1007/s11906-008-0040-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  10 in total

1.  Cardiovascular protection and blood pressure reduction: a meta-analysis.

Authors:  J A Staessen; J G Wang; L Thijs
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

4.  Blood pressure reduction is not the only determinant of outcome.

Authors:  Peter S Sever; Neil R Poulter; William J Elliott; M Charlotte Jonsson; Henry R Black; Peter S Sever; Neil R Poulter; William J Elliott; M Charlotte Jonsson; Henry R Black
Journal:  Circulation       Date:  2006-06-13       Impact factor: 29.690

Review 5.  European Society of Hypertension Scientific Newsletter: Clinical value of ambulatory blood pressure monitoring.

Authors:  Jean-Michel Mallion; Jean-Philippe Baguet; Giuseppe Mancia
Journal:  J Hypertens       Date:  2006-11       Impact factor: 4.844

6.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

7.  Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

Authors:  P Svensson; U de Faire; P Sleight; S Yusuf; J Ostergren
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Effect of different antihypertensive drug classes on central aortic pressure.

Authors:  Trefor Morgan; Jann Lauri; Denise Bertram; Adrianne Anderson
Journal:  Am J Hypertens       Date:  2004-02       Impact factor: 2.689

10.  Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy.

Authors:  Lia E Bang; Niels Wiinberg; Kristian Wachtell; John Larsen; Michael H Olsen; Christian Tuxen; Per R Hildebrandt; Hans Ibsen
Journal:  Blood Press       Date:  2007       Impact factor: 2.835
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.